No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis.
Härle
P
P
Sarzi-Puttini
P
P
Cutolo
M
M
Straub
R H
RH
D000068879:Adalimumab; D052242:Adiponectin / Q000097:blood*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy / Q000276:immunology; D005260:Female; D006801:Humans; D020738:Leptin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D052242:Adiponectin; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D020738:Leptin; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab